Publication: Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand
Issued Date
2013-10-01
Resource Type
ISSN
18792472
00493848
00493848
Other identifier(s)
2-s2.0-84885179289
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Thrombosis Research. Vol.132, No.4 (2013), 437-443
Suggested Citation
Surasak Saokaew, Unchalee Permsuwan, Nathorn Chaiyakunapruk, Surakit Nathisuwan, Apichard Sukonthasarn, Napawan Jeanpeerapong Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand. Thrombosis Research. Vol.132, No.4 (2013), 437-443. doi:10.1016/j.thromres.2013.08.019 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32148
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand
Abstract
Introduction Although pharmacist-participated warfarin therapy management (PWTM) is well established, the economic evaluation of PWTM is still lacking particularly in Asia-Pacific region. The objective of this study was to estimate the cost-effectiveness of PWTM in Thailand using local data where available. Methods A Markov model was used to compare lifetime costs and quality-adjusted life years (QALYs) accrued to patients receiving warfarin therapy through PWTM or usual care (UC). The model was populated with relevant information from both health care system and societal perspectives. Input data were obtained from literatures and database analyses. Incremental cost-effectiveness ratios (ICERs) were presented as year 2012 values. A base-case analysis was performed for patients at age 45 years old. Sensitivity analyses including one-way and probabilistic sensitivity analyses were constructed to determine the robustness of the findings. Results From societal perspective, PWTM and UC results in 39.5 and 38.7 QALY, respectively. Thus, PWTM increase QALY by 0.79, and increase costs by 92,491 THB (3,083 USD) compared with UC (ICER 116,468 THB [3,882.3 USD] per QALY gained). While, from health care system perspective, PWTM also results in 0.79 QALY, and increase costs by 92,788 THB (3,093 USD) compared with UC (ICER 116,842 THB [3,894.7 USD] per QALY gained). Thus, PWTM was cost-effective compared with usual care, assuming willingness-to-pay (WTP) of 150,000 THB/QALY. Results were sensitive to the discount rate and cost of clinic set-up. Conclusion Our finding suggests that PWTM is a cost-effective intervention. Policy-makers may consider our finding as part of information in their decision-making for implementing this strategy into healthcare benefit package. Further updates when additional data available are needed. © 2013 Elsevier Ltd.